Barrow, Hanley, Mewhinney & Strauss’s Medifast MED Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-969	Closed	-$10.3K	–	404
2025 Q4	$10.3K	Hold	969	–	–	﹤0.01%	214
2025 Q3	$13.2K	Hold	969	–	–	﹤0.01%	190
2025 Q2	$13.6K	Buy	+969	New	+$12.7K	﹤0.01%	185
2016 Q3	–	Sell	-70,329	Closed	-$2.34M	–	331
2016 Q2	$2.34M	Sell	70,329 -18	-0%	-$581	﹤0.01%	245
2016 Q1	$2.12M	Sell	70,347 -20,037	-22%	-$586K	﹤0.01%	245
2015 Q4	$2.75M	Buy	90,384 +2,600	+3%	+$77.4K	﹤0.01%	214
2015 Q3	$2.36M	Buy	87,784 +17	+0%	+$495	﹤0.01%	222
2015 Q2	$2.84M	Buy	87,767 +4,745	+6%	+$150K	﹤0.01%	210
2015 Q1	$2.49M	Buy	+83,022	New	+$2.64M	﹤0.01%	217

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCP

Steamboat Capital Partners Rye, New York $468M AUM 80.81% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's MED Position: Q1 2026 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of Medifast (MED) in Q1 2026, closing a stake of 969 shares — an estimated $10.3K sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in MED in Q1 2015 and held it in 9 quarters. The position peaked at $2.84M in Q2 2015. 112 funds tracked by Wall St. Rank hold MED as of Q1 2026.

Barrow, Hanley, Mewhinney & Strauss reported no remaining Medifast position as of Q1 2026 after selling out during the quarter.
Barrow, Hanley, Mewhinney & Strauss sold 969 Medifast shares in Q1 2026, an estimated $10.3K.
Barrow, Hanley, Mewhinney & Strauss first reported a position in Medifast in Q1 2015 and held it in 9 quarters.
Barrow, Hanley, Mewhinney & Strauss's Medifast position peaked at $2.84M in Q2 2015.
112 funds tracked by Wall St. Rank held Medifast as of Q1 2026.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q1 2026, filed 13 May 2026.